Data gathered: November 27
Alternative Data for Soligenix
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 331 | Sign up | Sign up | Sign up |
| Instagram Followers | 215 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,240 | Sign up | Sign up | Sign up |
| Twitter Followers | 938 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,680 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 23 | Sign up | Sign up | Sign up |
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
| Price | $3.33 |
| Target Price | Sign up |
| Volume | 10,300 |
| Market Cap | $8.4M |
| Year Range | $2 - $10.24 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical NeedsNovember 26 - Biztoc.com |
 |
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNovember 18 - Yahoo |
 |
Soligenix to Present at November 21st Virtual Investor Summit Microcap EventNovember 14 - Yahoo |
 |
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood VesselsNovember 13 - Yahoo |
|
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 13 - Yahoo |
 |
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024November 10 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 0 | -900,000 | -1.7M | -1.9M | -0.780 |
| Q2 '24 | 2,300 | 2,300 | 0 | -1.6M | -1.7M | -1.310 |
| Q1 '24 | 120,000 | 120,000 | 0 | -1.9M | -1.9M | -0.180 |
| Q4 '23 | 240,000 | 220,000 | 23,000 | -1.8M | -2.3M | -0.230 |
| Q3 '23 | 130,000 | 110,000 | 20,000 | -1.7M | -1.8M | -0.160 |
Insider Transactions View All
| Straube Richard filed to buy 8,000 shares at $0.5. May 18 '22 |
| SCHABER CHRISTOPHER J filed to buy 90,095 shares at $0.4. May 18 '22 |
Similar companies
Read more about Soligenix (SNGX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Soligenix?
The Market Cap of Soligenix is $8.4M.
What is the current stock price of Soligenix?
Currently, the price of one share of Soligenix stock is $3.33.
How can I analyze the SNGX stock price chart for investment decisions?
The SNGX stock price chart above provides a comprehensive visual representation of Soligenix's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Soligenix shares. Our platform offers an up-to-date SNGX stock price chart, along with technical data analysis and alternative data insights.
Does SNGX offer dividends to its shareholders?
As of our latest update, Soligenix (SNGX) does not offer dividends to its shareholders. Investors interested in Soligenix should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Soligenix?
Some of the similar stocks of Soligenix are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.